Search filters

List of works by Emiliano Calvo

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

scientific article published on 8 December 2016

A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer

scientific article published on 24 April 2015

A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

scientific article published on 28 January 2019

A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR

scientific article published on 18 March 2020

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours

scientific article published on 01 October 2018

A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer

scientific article published on 06 March 2017

Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer

scientific article published on April 2014

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers

scientific article published on 01 February 2019

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study

scientific article

Corrigendum to 'A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours' [Eur J Cancer 104 (November 2018) 1-8]

scientific article published on 30 July 2019

Design and conduct of early clinical studies of immunotherapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)

scientific article published on 21 February 2020

Early-phase clinical drug development of novel agents: a changing paradigm

scientific article published on 01 July 2019

Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer.

scientific article

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

scientific article published on 31 January 2018

Increased vulnerability of clinical research units during the COVID-19 crisis and their protection

scientific article published on 02 June 2020

Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer

scientific article published on 15 March 2019

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

scientific article published on 14 May 2019

New designs in early clinical drug development

scientific article published on 01 September 2019

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

scientific article published on 17 May 2019

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

scientific article published on 17 October 2019

Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 study

scientific article published on 01 June 2017

Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancer.

scientific article

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

scientific article

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

scientific article published on 15 February 2019

Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors

scientific article published on 12 December 2014

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.

scientific article published on 4 November 2015

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy ⬇️

scientific article published on September 7, 2011

Phase Ib Study of Ribociclib Plus Fulvestrant and Ribociclib Plus Fulvestrant Plus PI3K-Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer

scientific article published on 04 September 2020

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer

scientific article

Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft ⬇️

scientific article published on December 19, 2011

Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial

scientific article published on 15 October 2020

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

scientific article published on 10 July 2019

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors.

scientific article published in January 2018

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

scientific article published on 05 September 2019

Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)

scientific article published on 01 July 2019

T Cell-Engaging Therapy for Solid Tumors

scientific article published on 20 October 2020

The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma

scientific article published on 29 August 2018

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

scientific article published on 01 February 2019

What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? ⬇️

scientific article published on July 23, 2012

Paulina is supported by:

About Paulina

Help